Tardive Dyskinesia

Search with Google Search with Bing
Information
Disease name
Tardive Dyskinesia
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT02252380 Active, not recruiting N/A ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders May 2015 December 2023
NCT00190008 Completed Phase 3 Piracetam for Treatment Tardive Dyskinesia August 2003
NCT00291213 Completed Phase 3 Levetiracetam Treatment of Tardive Dyskinesia
NCT00401089 Completed Phase 1/Phase 2 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia December 2002 October 2007
NCT00672373 Completed Phase 3 Extract of Ginkgo Biloba and Tardive Dyskinesia December 2006 August 2007
NCT00164242 Completed Phase 4 Treatment of Tardive Dyskinesia With Galantamine January 2002 October 2004
NCT01467089 Completed The Assessment of Movement Disorders Utilizing Live Two-Way Video November 2011 June 2016
NCT01543321 Completed Phase 3 Xenazine in Late Dyskinetic Syndrome With Neuroleptics May 14, 2012 August 2017
NCT01688037 Completed Phase 2 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) September 2012 October 2013
NCT01733121 Completed Phase 2 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia December 2012 December 2013
NCT02195700 Completed Phase 2/Phase 3 Aim to Reduce Movements in Tardive Dyskinesia June 2014 May 2015
NCT02198794 Completed Phase 3 Reducing Involuntary Movements in Participants With Tardive Dyskinesia October 20, 2014 December 14, 2020
NCT02274558 Completed Phase 3 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia October 2014 July 2016
NCT02291861 Completed Phase 3 Addressing Involuntary Movements in Tardive Dyskinesia October 31, 2014 August 19, 2016
NCT02405091 Completed Phase 3 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia March 2015 March 2017
NCT02736955 Completed Phase 3 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia June 13, 2016 June 30, 2017
NCT03176771 Completed Phase 2/Phase 3 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia June 21, 2017 September 29, 2020
NCT03287778 Completed N/A Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia December 1, 2017 December 30, 2022
NCT03497013 Completed N/A Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia July 31, 2017 August 11, 2020
NCT04794413 Completed Early Phase 1 Pimavanserin Treatment in TS November 12, 2018 February 28, 2021
NCT05238701 Completed Phase 1 A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects February 25, 2022 November 4, 2023
NCT00926965 Completed Phase 4 Tardive Dyskinesia and Cognitive Function January 2003 December 2007
NCT01267188 Completed Phase 2 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia January 2011 March 2011
NCT01391390 Completed N/A Melatonin Treatment for Tardive Dyskinesia in Schizophrenia September 2008 May 2011
NCT01393600 Completed Phase 2 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder August 2011 February 2012
NCT06107829 Not yet recruiting Phase 4 Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities August 2024 August 2026
NCT06218719 Not yet recruiting Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients February 2025 February 2027
NCT05053321 Not yet recruiting Phase 1 Reduction of Demoralization After Treatment of TD With Valbenazine April 2024 July 2024
NCT05859698 Recruiting Phase 4 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia May 25, 2023 December 2024
NCT06216054 Recruiting Phase 1 Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects December 23, 2023 August 14, 2024
NCT06011408 Recruiting N/A Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes May 30, 2023 December 31, 2024
NCT03495024 Recruiting Phase 4 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates January 1, 2019 June 30, 2020
NCT02524886 Terminated N/A Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia June 2015 June 25, 2017
NCT00917293 Terminated Phase 2 Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia May 2009 August 2014
NCT00621634 Unknown status Phase 2 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia February 2008
NCT03062033 Unknown status Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents April 4, 2017 August 2018
NCT01804920 Unknown status N/A D-Serine Treatment For Tardive Dyskinesia January 2013 January 2019
NCT02840760 Unknown status N/A Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. September 2016 December 2018
NCT03254186 Withdrawn Phase 2/Phase 3 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia September 18, 2017 February 1, 2019
NCT01908452 Withdrawn Phase 3 Pyridoxal Kinase Activity in Tardive Dyskinesia July 2011 July 2011
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0040141
MeSH unique ID (MeSH (Medical Subject Headings))
D000071057